New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
10:35 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho said the final CMS pricing for Myriad's BRCA testing represents a cut of about 20%, but that is still less severe than originally outlined. The firm raised its price target on Myriad Genetics to $40 following the ruling, but maintains its Neutral rating on the stock.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:45 EDTMYGNMyriad Genetics presents tumor BRACAnalysis CDx study at ESMO
Subscribe for More Information
07:24 EDTMYGNStephens to hold an investor trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use